• Joshua Manuel Martens, Kenneth Fiala, Christopher Glover, Nicholas Zacharias, and Alaa Abd-Elsayed.
• Department of Anesthesiology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
• Neuromodulation. 2023 Jan 1; 26 (1): 435643-56.

ObjectivesTo assess the currently available evidence regarding associations between spinal cord stimulator (SCS) lead type, clinical indications for device placement, and interference between SCSs and cardiac pacemakers (CPMs)/implantable cardioverter-defibrillators (ICDs).Study DesignReview of case reports and original research studies assessing the interference between SCS and CPM/ICD.Materials And MethodsPubMed and Cochrane databases were searched for articles commenting on the interference between SCS and CPM/ICD. The search criteria which generated the greatest number of relevant studies was (spinal cord stimulator AND [pacemaker OR implantable cardioverter defibrillator]). Additional, empiric review was conducted using JSTOR, ScienceDirect, and EBSCOhost databases; however, no additional eligible studies were identified. Data were extracted, summarized into tables, and quantitatively analyzed using LibreTexts and MedCalc software.ResultsThere was no statistically significant interference observed between SCS and CPM/ICD devices in patients regardless of indication for SCS placement and SCS lead polarity.LimitationsLimited by variability of patient cases and variability in maximum frequency and amplitude of SCS devices tried in individual cases. Also limited by small sample size and the absence of a standard definition for device interference across studies.ConclusionsInterference between cardiac devices and SCSs is a rare occurrence. As there are currently no published guidelines, devices should be interrogated on a case-by-case basis in the SCS trial period (if implanted after cardiac device), during permanent implantation, and during scheduled follow-up visits. Peri-operative testing should include increasing the SCS settings to maximally tolerated levels with cardiac device set at its maximum sensitivity.Copyright © 2022. Published by Elsevier Inc.

13 keywords...

hide…